Alzheimer's disease is characterized by the accumulation of particular toxic proteins in the brain that are believed to underlie the cognitive decline in patients. A new study conducted in mice suggests that newly identified antibody treatments can prevent the accumulation of one of these of these toxic components, called tau proteins. The findings, online September 26 in the Cell Press journal Neuron, suggest that these antibodies may provide a basis for a promising therapy for patients with Alzheimer's disease and other neurodegenerative disorders.
↧